Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance

Journal of Hypertension

Volumn 33, Issue 12, 2015, Pages 2519-2525

  Ewen, Sebastian ^a   Cremers, Bodo ^a   Meyer, Markus R ^b   Donazzan, Luca ^a   Kindermann, Ingrid ^a   Ukena, Christian ^a   Helfer, Andreas G ^b   Maurer, Hans H ^b   Laufs, Ulrich ^a   Grassi, Guido ^c,d   Böhm, Michael ^a   Mahfoud, Felix ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

adherence; arterial stiffness; renal denervation; resistant hypertension; sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; RENIN; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT;

ABLATION CATHETER; ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CATHETER BASED RENAL DENERVATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART OUTPUT; HEART RATE; HUMAN; KIDNEY DENERVATION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY HIGH RESOLUTION TANDEM MASS SPECTROMETRY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RADIOFREQUENCY; RADIOFREQUENCY ABLATION; RESISTANT HYPERTENSION; TANDEM MASS SPECTROMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; VASCULAR RESISTANCE; AGED; BLOOD; CATHETER ABLATION; CORONARY VASOSPASM; HYPERTENSION; INNERVATION; KIDNEY ARTERY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYMPATHECTOMY;

AGED; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIAC OUTPUT; CATHETER ABLATION; CORONARY VASOSPASM; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; RENAL ARTERY; RENIN; SYMPATHECTOMY; VASCULAR RESISTANCE;

EID: 84947023447     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000752     Document Type: Article

References (37)

1. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015; 116:976-990.
2. Wallace SM, Yasmin. McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007; 50:228-233.
3. Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013; 166:306-314.
4. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005; 289:R633-R641.
5. Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 2014; 64:118-124.
6. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatmentresistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383:622-629.
7. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35:1752-1759.
8. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65:766-774.
9. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128:132-140.
10. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957-1965.
11. Mahfoud F, Luscher TF. Renal denervation: symply trapped by complexity? Eur Heart J 2015; 36:199-202.
12. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-1401.
13. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015; 65:193-199.
14. Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, et al. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. EuroIntervention 2015; 11:110-116.
15. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60:1956-1965.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
17. Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, et al. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESHWGon the interventional treatment of hypertension. EuroIntervention 2014; 9:1027-1035.
18. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res 1998; 38:605-616.
19. Wesseling KH. A century of noninvasive arterial pressure measurement: from Marey to Penaz and Finapres. Homeostasis 1996; 36:2-3.
20. Truijen J, van Lieshout JJ, Wesselink WA, Westerhof BE. Noninvasive continuous hemodynamic monitoring. J Clin Monit Comput 2012; 26:267-278.
21. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359-1366.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005; 18:1440-1463.
23. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10:165-193.
24. Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH. Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 2011; 400:79-88.
25. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 2015; 65:407-413.
26. Grassi G, Seravalle G, Brambilla G, Trabattoni D, Cuspidi C, Corso R, et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension 2015; 65:1209-1216.
27. Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, et al. From SYMPLICITY HTN-3 to the renal denervation global registry: where do we stand and where should we go? EuroIntervention 2014; 10:21-23.
28. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; doi: http://dx. doi. org/10. 1093/eurheartj/ehv192 First published online: 19 May 2015.
29. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36:219-227.
30. Mahfoud F, Edelman ER, Böhm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014; 64:644-646.
31. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004; 17 (12 Pt):1192-1200.
32. Pöss J, Ewen S, Schmieder RE, Muhler S, Vonend O, Ott C, et al. Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol 2015; 104:672-678.
33. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
34. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67:267-277.
35. Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after Symplicity HTN-3: an update. Curr Hypertens Rep 2014; 16:460.
36. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766-774.
37. Baranda AB, Alonso RM, Jimenez RM, Weinmann W. Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples. Forensic Sci Int 2006; 156:23-34.